ArticleJCO precision oncology2026

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

David Milewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.